LeMaitre Vascular, Inc.
NASDAQ:LMATMedical - Instruments & Supplies
+$1.60 today
- Market cap
- $1.73B
- Beta
- 0.52
- P/E (TTM)
- 34.3
- EPS (TTM)
- $2.74
- Dividend yield
- 0.96%
Volume 0.22M
Average 0.26M
LMAT Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
LeMaitre Vascular, Inc.NASDAQ: LMAT
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $3.22M (cash outflow) fell 38.6% year over year, ahead of the -108.2% change in trailing-twelve-month financing cash flow. Sequentially, it fell 10.3% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.
Context
- Financing cash flow amounted to 5.8% of revenue in FY2025, down 66.1 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -38.6% holds above the trailing-twelve-month pace of -108.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (14.54M) USD
- Year-over-year change
- -109.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (14.54M) | -109.2% |
| FY2024 | 2024-12-31 | 158.1M | +2317.1% |
| FY2023 | 2023-12-31 | (7.13M) | +22.8% |
| FY2022 | 2022-12-31 | (9.23M) | -167.4% |
| FY2021 | 2021-12-31 | 13.7M | — |
Financing Cash Flow vs competitors
How LMAT compares with its peers on the latest reported figures
- LMAT's LTM Mar 2026 financing cash flow of $12.52M is the 5th largest of the 8 companies compared; the peer median is $5.06M.
- Its year-over-year change of -108.2% is the 6th highest of 8, against a peer median of -25.9%.
- Financing cash flow amounts to 4.9% of revenue for LMAT, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $3.71B | -25.9% | -1.4% | 9.9% | |
| LTM Jun 2026 | $958M | -940.4% | -10.3% | 4.6% | |
| LTM Jun 2026 | $449.36M | +219.2% | — | 17.3% | |
| LTM Jun 2026 | $16.13M | +121.0% | +31.7% | 1.1% | |
| LTM Mar 2026 | $12.52M | -108.2% | +16.3% | 4.9% | |
| LTM Mar 2026 | $9.56M | +76.9% | — | 2.1% | |
| LTM Feb 2026 | $5.1M | -1089.9% | — | 1.6% | |
| LTM Sep 2026 | $5.06M | -62.1% | — | 0.3% | |
| Peer median (excluding LMAT) | $5.06M | -25.9% | -1.4% | 2.1% | |
Competitors are the stored peer set for LMAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 26.91M | 20.64M | 30.11M | 44.04M | 57.73M |
| Depreciation & Amortization | 11.07M | 9.43M | 9.52M | 9.67M | 10.42M |
| Deferred Income Tax | 79K | (182K) | 783K | (451K) | 2.31M |
| Stock-Based Compensation | 3.48M | 4.17M | 5.32M | 6.57M | 7.83M |
| Change in Working Capital | (9.96M) | (13.4M) | (11.25M) | (20.1M) | (1.75M) |
| Accounts Receivables | (818K) | (3.53M) | (3.14M) | (6.42M) | (2.95M) |
| Inventory | (5.49M) | (7.42M) | (9.79M) | (10.57M) | (7.22M) |
| Accounts Payables | (1.73M) | 645K | 4.6M | (779K) | 4.2M |
| Other Working Capital | (1.93M) | (3.1M) | (2.92M) | (2.33M) | 4.22M |
| Other Non-Cash Items | 3.53M | 4.72M | 2.28M | 4.4M | 4.71M |
| Operating Cash Flow | 35.1M | 25.38M | 36.75M | 44.12M | 81.25M |
| Capital Expenditures | (4.88M) | (3.23M) | (7.27M) | (6.96M) | (6.78M) |
| Acquisitions (Net) | 0 | 0 | (899K) | 0 | (1.9M) |
| Purchases of Investments | (59.19M) | (8M) | (16.55M) | (277.94M) | (641.33M) |
| Sales of Investments | 3M | 0 | 0 | 84.78M | 585.07M |
| Other Investing Activities | 0 | 858K | 0 | 0 | 0 |
| Investing Cash Flow | (61.08M) | (10.37M) | (24.72M) | (200.12M) | (64.94M) |
| Debt Repayment | (39M) | 0 | 0 | 169.27M | 0 |
| Common Stock Issued | 63.24M | 3.47M | 6.17M | 6.44M | 6.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (9.34M) | (10.99M) | (12.45M) | (14.38M) | (18.11M) |
| Other Financing Activities | (1.2M) | (1.71M) | (853K) | (3.23M) | (3.25M) |
| Financing Cash Flow | 13.7M | (9.23M) | (7.13M) | 158.1M | (14.54M) |
| Effect of Forex Changes | (637K) | (494K) | 230K | (765K) | 864K |
| Net Change in Cash | (12.91M) | 5.28M | 5.14M | 1.34M | 2.63M |
| Free Cash Flow | 30.22M | 22.15M | 29.49M | 37.16M | 74.47M |
LeMaitre Vascular, Inc.
NASDAQ:LMAT
Intrinsic Alpha fair value
Locked
Current Price
$75.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.